Economic Burden of Adult Pharyngitis: The Payer's Perspective

Abstract Objectives Although not recommended by practice guidelines, physicians frequently prescribe an antibiotic for adults with viral pharyngitis. The financial burden of this practice, from the payer's perspective, has not been previously evaluated. The purpose of this study was to estimate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Value in health 2008-07, Vol.11 (4), p.621-627
Hauptverfasser: Salkind, Alan R., MD, Wright, Julie M., PharmD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 627
container_issue 4
container_start_page 621
container_title Value in health
container_volume 11
creator Salkind, Alan R., MD
Wright, Julie M., PharmD
description Abstract Objectives Although not recommended by practice guidelines, physicians frequently prescribe an antibiotic for adults with viral pharyngitis. The financial burden of this practice, from the payer's perspective, has not been previously evaluated. The purpose of this study was to estimate those expenditures. Methods A cost-of-illness study was performed to estimate annual expenditures of pharyngitis management from the payer's perspective. National Ambulatory Care Survey data were used to represent current patterns of ambulatory care visits and antibiotic prescriptions for adult pharyngitis. Direct and antibiotic resistance costs were summed to estimate total expenditures for pharyngitis management. Resistance costs were calculated using a model linking the effect of antibiotic consumption to the cost consequences of resistant Streptococcus pneumoniae infection. Sensitivity analyses compared cost outcomes of current practice, adherence to pharyngitis management guidelines from the Infectious Diseases Society of America (IDSA), and nonantibiotic treatment. Results In the base-case analysis, reflecting current practice patterns, total expenditures were $1.2 billion with antibiotic resistance contributing 36% ($426 million). IDSA guideline adherence decreased costs to $559 million with resistance accounting for 6.8% ($37.9 million). Guideline adherence plus reducing office visits by 30% decreased costs to $372 million, with only 1.4% ($5.3 million) due to resistance. Additional cost-savings of $88 million were realized by using a nonantibiotic treatment strategy. Conclusions Current practice imposed a substantial economic burden on the payer, while guideline adherence resulted in cost reductions, especially in terms of resistance, emphasizing that antibiotic prescribing habits have broad economic consequences. Relevant stakeholders, payers, physicians, and other health-care providers should revisit efforts to encourage adherence to pharyngitis guidelines to reduce health-care costs.
doi_str_mv 10.1111/j.1524-4733.2007.00286.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754140106</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1098301510605396</els_id><sourcerecordid>754140106</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5936-8f1c4f4256a66f81fad41b5fecdf44b629e66f99d770cd96a2eea55d7c2982523</originalsourceid><addsrcrecordid>eNqNkk1vEzEQhi0EoiXwF9Ce6Gm3ttefCJDaKlCkSkSicLUce0wdNrupnS3Nv8fbRCBxQPXFI_t9ZzyPB6GK4IaUdbpqCKesZrJtG4qxbDCmSjT3T9Dxn4unJcZa1S0m_Ai9yHmFMRYt5c_REVFEaiHZMXo_d0M_rKOrzsfkoa-GUJ35sdtWixubdv2PuI35bXV9A9XC7iCd5GoBKW_AbeMdvETPgu0yvDrsM_Tt4_z64rK--vLp88XZVe24bkWtAnEsMMqFFSIoEqxnZMkDOB8YWwqqoZxr7aXEzmthKYDl3EtHtaKctjN0ss-7ScPtCHlr1jE76DrbwzBmIzkjDJPS3gy9-a-SaKWlZKoI1V7o0pBzgmA2Ka5Ly4ZgM0E2KzOxNBNLM0E2D5DNfbG-PtQYl2vwf40HqkXwbi_4FTvYPTqx-X45L0Gxn-_tUJDeRUgmuwi9Ax9T4W78EB_zyA__JHFd7KOz3U_YQV4NY-rLlxliMjXYfJ1mZRqVAhHzVov2N4X4szk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19897748</pqid></control><display><type>article</type><title>Economic Burden of Adult Pharyngitis: The Payer's Perspective</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Salkind, Alan R., MD ; Wright, Julie M., PharmD</creator><creatorcontrib>Salkind, Alan R., MD ; Wright, Julie M., PharmD</creatorcontrib><description>Abstract Objectives Although not recommended by practice guidelines, physicians frequently prescribe an antibiotic for adults with viral pharyngitis. The financial burden of this practice, from the payer's perspective, has not been previously evaluated. The purpose of this study was to estimate those expenditures. Methods A cost-of-illness study was performed to estimate annual expenditures of pharyngitis management from the payer's perspective. National Ambulatory Care Survey data were used to represent current patterns of ambulatory care visits and antibiotic prescriptions for adult pharyngitis. Direct and antibiotic resistance costs were summed to estimate total expenditures for pharyngitis management. Resistance costs were calculated using a model linking the effect of antibiotic consumption to the cost consequences of resistant Streptococcus pneumoniae infection. Sensitivity analyses compared cost outcomes of current practice, adherence to pharyngitis management guidelines from the Infectious Diseases Society of America (IDSA), and nonantibiotic treatment. Results In the base-case analysis, reflecting current practice patterns, total expenditures were $1.2 billion with antibiotic resistance contributing 36% ($426 million). IDSA guideline adherence decreased costs to $559 million with resistance accounting for 6.8% ($37.9 million). Guideline adherence plus reducing office visits by 30% decreased costs to $372 million, with only 1.4% ($5.3 million) due to resistance. Additional cost-savings of $88 million were realized by using a nonantibiotic treatment strategy. Conclusions Current practice imposed a substantial economic burden on the payer, while guideline adherence resulted in cost reductions, especially in terms of resistance, emphasizing that antibiotic prescribing habits have broad economic consequences. Relevant stakeholders, payers, physicians, and other health-care providers should revisit efforts to encourage adherence to pharyngitis guidelines to reduce health-care costs.</description><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1111/j.1524-4733.2007.00286.x</identifier><identifier>PMID: 18179674</identifier><language>eng</language><publisher>Malden, USA: Elsevier Inc</publisher><subject>Acute Disease ; Adherence ; Adult ; adults ; Ambulatory Care - economics ; Anti-Bacterial Agents - administration &amp; dosage ; Anti-Bacterial Agents - adverse effects ; Anti-Bacterial Agents - economics ; antibiotic resistance ; Antibiotics ; Burden ; Cohort Studies ; Cost of Illness ; cost-of-illness analysis ; Drug Resistance, Microbial ; Expenditure ; Guideline Adherence - statistics &amp; numerical data ; Health Care Costs - statistics &amp; numerical data ; Humans ; Internal Medicine ; Pharyngitis ; Pharyngitis - drug therapy ; Pharyngitis - economics ; Practice Patterns, Physicians' - statistics &amp; numerical data ; Resistance</subject><ispartof>Value in health, 2008-07, Vol.11 (4), p.621-627</ispartof><rights>International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><rights>2008 International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><rights>2007, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5936-8f1c4f4256a66f81fad41b5fecdf44b629e66f99d770cd96a2eea55d7c2982523</citedby><cites>FETCH-LOGICAL-c5936-8f1c4f4256a66f81fad41b5fecdf44b629e66f99d770cd96a2eea55d7c2982523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1524-4733.2007.00286.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1098301510605396$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,3537,27901,27902,30977,45550,45551,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18179674$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salkind, Alan R., MD</creatorcontrib><creatorcontrib>Wright, Julie M., PharmD</creatorcontrib><title>Economic Burden of Adult Pharyngitis: The Payer's Perspective</title><title>Value in health</title><addtitle>Value Health</addtitle><description>Abstract Objectives Although not recommended by practice guidelines, physicians frequently prescribe an antibiotic for adults with viral pharyngitis. The financial burden of this practice, from the payer's perspective, has not been previously evaluated. The purpose of this study was to estimate those expenditures. Methods A cost-of-illness study was performed to estimate annual expenditures of pharyngitis management from the payer's perspective. National Ambulatory Care Survey data were used to represent current patterns of ambulatory care visits and antibiotic prescriptions for adult pharyngitis. Direct and antibiotic resistance costs were summed to estimate total expenditures for pharyngitis management. Resistance costs were calculated using a model linking the effect of antibiotic consumption to the cost consequences of resistant Streptococcus pneumoniae infection. Sensitivity analyses compared cost outcomes of current practice, adherence to pharyngitis management guidelines from the Infectious Diseases Society of America (IDSA), and nonantibiotic treatment. Results In the base-case analysis, reflecting current practice patterns, total expenditures were $1.2 billion with antibiotic resistance contributing 36% ($426 million). IDSA guideline adherence decreased costs to $559 million with resistance accounting for 6.8% ($37.9 million). Guideline adherence plus reducing office visits by 30% decreased costs to $372 million, with only 1.4% ($5.3 million) due to resistance. Additional cost-savings of $88 million were realized by using a nonantibiotic treatment strategy. Conclusions Current practice imposed a substantial economic burden on the payer, while guideline adherence resulted in cost reductions, especially in terms of resistance, emphasizing that antibiotic prescribing habits have broad economic consequences. Relevant stakeholders, payers, physicians, and other health-care providers should revisit efforts to encourage adherence to pharyngitis guidelines to reduce health-care costs.</description><subject>Acute Disease</subject><subject>Adherence</subject><subject>Adult</subject><subject>adults</subject><subject>Ambulatory Care - economics</subject><subject>Anti-Bacterial Agents - administration &amp; dosage</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Anti-Bacterial Agents - economics</subject><subject>antibiotic resistance</subject><subject>Antibiotics</subject><subject>Burden</subject><subject>Cohort Studies</subject><subject>Cost of Illness</subject><subject>cost-of-illness analysis</subject><subject>Drug Resistance, Microbial</subject><subject>Expenditure</subject><subject>Guideline Adherence - statistics &amp; numerical data</subject><subject>Health Care Costs - statistics &amp; numerical data</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Pharyngitis</subject><subject>Pharyngitis - drug therapy</subject><subject>Pharyngitis - economics</subject><subject>Practice Patterns, Physicians' - statistics &amp; numerical data</subject><subject>Resistance</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqNkk1vEzEQhi0EoiXwF9Ce6Gm3ttefCJDaKlCkSkSicLUce0wdNrupnS3Nv8fbRCBxQPXFI_t9ZzyPB6GK4IaUdbpqCKesZrJtG4qxbDCmSjT3T9Dxn4unJcZa1S0m_Ai9yHmFMRYt5c_REVFEaiHZMXo_d0M_rKOrzsfkoa-GUJ35sdtWixubdv2PuI35bXV9A9XC7iCd5GoBKW_AbeMdvETPgu0yvDrsM_Tt4_z64rK--vLp88XZVe24bkWtAnEsMMqFFSIoEqxnZMkDOB8YWwqqoZxr7aXEzmthKYDl3EtHtaKctjN0ss-7ScPtCHlr1jE76DrbwzBmIzkjDJPS3gy9-a-SaKWlZKoI1V7o0pBzgmA2Ka5Ly4ZgM0E2KzOxNBNLM0E2D5DNfbG-PtQYl2vwf40HqkXwbi_4FTvYPTqx-X45L0Gxn-_tUJDeRUgmuwi9Ax9T4W78EB_zyA__JHFd7KOz3U_YQV4NY-rLlxliMjXYfJ1mZRqVAhHzVov2N4X4szk</recordid><startdate>200807</startdate><enddate>200807</enddate><creator>Salkind, Alan R., MD</creator><creator>Wright, Julie M., PharmD</creator><general>Elsevier Inc</general><general>Blackwell Publishing Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7QJ</scope></search><sort><creationdate>200807</creationdate><title>Economic Burden of Adult Pharyngitis: The Payer's Perspective</title><author>Salkind, Alan R., MD ; Wright, Julie M., PharmD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5936-8f1c4f4256a66f81fad41b5fecdf44b629e66f99d770cd96a2eea55d7c2982523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acute Disease</topic><topic>Adherence</topic><topic>Adult</topic><topic>adults</topic><topic>Ambulatory Care - economics</topic><topic>Anti-Bacterial Agents - administration &amp; dosage</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Anti-Bacterial Agents - economics</topic><topic>antibiotic resistance</topic><topic>Antibiotics</topic><topic>Burden</topic><topic>Cohort Studies</topic><topic>Cost of Illness</topic><topic>cost-of-illness analysis</topic><topic>Drug Resistance, Microbial</topic><topic>Expenditure</topic><topic>Guideline Adherence - statistics &amp; numerical data</topic><topic>Health Care Costs - statistics &amp; numerical data</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Pharyngitis</topic><topic>Pharyngitis - drug therapy</topic><topic>Pharyngitis - economics</topic><topic>Practice Patterns, Physicians' - statistics &amp; numerical data</topic><topic>Resistance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salkind, Alan R., MD</creatorcontrib><creatorcontrib>Wright, Julie M., PharmD</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salkind, Alan R., MD</au><au>Wright, Julie M., PharmD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Economic Burden of Adult Pharyngitis: The Payer's Perspective</atitle><jtitle>Value in health</jtitle><addtitle>Value Health</addtitle><date>2008-07</date><risdate>2008</risdate><volume>11</volume><issue>4</issue><spage>621</spage><epage>627</epage><pages>621-627</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><abstract>Abstract Objectives Although not recommended by practice guidelines, physicians frequently prescribe an antibiotic for adults with viral pharyngitis. The financial burden of this practice, from the payer's perspective, has not been previously evaluated. The purpose of this study was to estimate those expenditures. Methods A cost-of-illness study was performed to estimate annual expenditures of pharyngitis management from the payer's perspective. National Ambulatory Care Survey data were used to represent current patterns of ambulatory care visits and antibiotic prescriptions for adult pharyngitis. Direct and antibiotic resistance costs were summed to estimate total expenditures for pharyngitis management. Resistance costs were calculated using a model linking the effect of antibiotic consumption to the cost consequences of resistant Streptococcus pneumoniae infection. Sensitivity analyses compared cost outcomes of current practice, adherence to pharyngitis management guidelines from the Infectious Diseases Society of America (IDSA), and nonantibiotic treatment. Results In the base-case analysis, reflecting current practice patterns, total expenditures were $1.2 billion with antibiotic resistance contributing 36% ($426 million). IDSA guideline adherence decreased costs to $559 million with resistance accounting for 6.8% ($37.9 million). Guideline adherence plus reducing office visits by 30% decreased costs to $372 million, with only 1.4% ($5.3 million) due to resistance. Additional cost-savings of $88 million were realized by using a nonantibiotic treatment strategy. Conclusions Current practice imposed a substantial economic burden on the payer, while guideline adherence resulted in cost reductions, especially in terms of resistance, emphasizing that antibiotic prescribing habits have broad economic consequences. Relevant stakeholders, payers, physicians, and other health-care providers should revisit efforts to encourage adherence to pharyngitis guidelines to reduce health-care costs.</abstract><cop>Malden, USA</cop><pub>Elsevier Inc</pub><pmid>18179674</pmid><doi>10.1111/j.1524-4733.2007.00286.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1098-3015
ispartof Value in health, 2008-07, Vol.11 (4), p.621-627
issn 1098-3015
1524-4733
language eng
recordid cdi_proquest_miscellaneous_754140106
source Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; Wiley Online Library Journals Frontfile Complete; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Acute Disease
Adherence
Adult
adults
Ambulatory Care - economics
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - adverse effects
Anti-Bacterial Agents - economics
antibiotic resistance
Antibiotics
Burden
Cohort Studies
Cost of Illness
cost-of-illness analysis
Drug Resistance, Microbial
Expenditure
Guideline Adherence - statistics & numerical data
Health Care Costs - statistics & numerical data
Humans
Internal Medicine
Pharyngitis
Pharyngitis - drug therapy
Pharyngitis - economics
Practice Patterns, Physicians' - statistics & numerical data
Resistance
title Economic Burden of Adult Pharyngitis: The Payer's Perspective
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T21%3A15%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Economic%20Burden%20of%20Adult%20Pharyngitis:%20The%20Payer's%20Perspective&rft.jtitle=Value%20in%20health&rft.au=Salkind,%20Alan%20R.,%20MD&rft.date=2008-07&rft.volume=11&rft.issue=4&rft.spage=621&rft.epage=627&rft.pages=621-627&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1111/j.1524-4733.2007.00286.x&rft_dat=%3Cproquest_cross%3E754140106%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19897748&rft_id=info:pmid/18179674&rft_els_id=S1098301510605396&rfr_iscdi=true